Quick Takeaways
- Fairmount Funds Management LLC filed SCHEDULE 13D/A for Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value (VRDN).
- Disclosed ownership: 15%.
- Date of event: 23 Oct 2025.
Fairmount Funds Management LLC - 23 Oct 2025 SCHEDULE 13D/A Report for Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value (VRDN)
- Filing Manager
- Fairmount Funds Management LLC
- Reporting Manager
- Fairmount Funds Management LLC
- Symbol
- VRDN
- Shares outstanding
- 105,847,622 shares
- Disclosed Ownership
- 16,025,330 shares
- Ownership
- 15%
- Form type
- SCHEDULE 13D/A
- Filing time
- 27 Oct 2025, 16:31:36 UTC
- Date of event
- 23 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Fairmount Funds Management LLC disclosed 15% ownership in Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value (VRDN) on 23 Oct 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 27 Oct 2025, 16:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 15% | 16,025,330 | 0 | 16,025,330 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001802528 |
| Fairmount Healthcare Fund II GP LLC | 15% | 16,025,330 | 0 | 16,025,330 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001830382 |